I'll research INCY (Incyte) before writing the earnings preview. Let me start by gathering recent filings, transcripts, and news.I'll read the most recent earnings materials and get more recent news context.Let me get the year-ago Q2 2025 numbers for comparison, plus recent stock price and news context.Let me read the Vega Therapeutics acquisition details and the Q2 2025 release for YoY comparison.I have what I need. Let me quickly verify the most recent news flow around the print.# Incyte (INCY) — Q2 2026 Earnings Preview
INCY enters this print near 52-week highs. The stock closed at $118.90 on 7/27/26, up roughly 73% over the past 12 months (from ~$69 last July) — broadly in line with the XBI biotech index over that stretch, but with a notable acceleration since early June. The rally reflects growing investor confidence that Incyte can build a diversified, growth-oriented portfolio ahead of the eventual Jakafi patent cliff (~2028) rather than relying on a single cornerstone product.
That framing — "transition Incyte beyond a single cornerstone product toward a high-quality growth-oriented portfolio across Hematology, Oncology and Immunology" — is the lens through which management wants this quarter judged, and it's the debate that matters more than any single Q2 number.
Year-ago (Q2 2025) actuals to anchor YoY comps:
| Metric (Q2'25) | Value | YoY then |
|---|---|---|
| Total revenue | $1,215.5M | +16% |
| Total net product revenue | $1,059.4M | +17% |
| Jakafi | $763.8M | +8% |
| Opzelura | $164.5M | +35% |
| Niktimvo | $36.2M | NM (launch) |
| Monjuvi/Minjuvi | $31.1M | flat |
| Zynyz | $8.9M | launch |
| Iclusig / Pemazyre | $32.7M / $22.2M | +22% / +9% |
| Royalty revenue | $151.1M | +10% |
| Non-GAAP diluted EPS | $1.57 | — |
Sequential (Q1 2026) actuals for momentum: - Total revenue $1.27B (+21% YoY), net sales $1.10B (+20% YoY) - Jakafi $758M (+7%); Opzelura $143M (+20%); Heme/Onc portfolio $204M (+116%) — Niktimvo $55M, Monjuvi $49M, Zynyz $41M - GAAP diluted EPS $1.47; Non-GAAP diluted EPS $1.81 - Cash/marketable securities $4.0B at 3/31/26
What this implies for Q2 2026: Full-year guidance points to double-digit growth, so the Street will be looking for net sales in roughly the $1.2–1.3B range, with the "core ex-Jakafi" business (Opzelura + Heme/Onc) again driving the growth delta. Watch specifically: - Jakafi durability — Q1 grew a slower +7% on +6% paid demand; is demand holding as the XR transition begins? - Heme/Onc portfolio — grew 116% in Q1; Niktimvo, Monjuvi (follicular lymphoma) and Zynyz (SCAC) are the swing factors. - Opzelura — U.S. NBRx share and the ex-U.S. vitiligo ramp.
At Q1, Incyte reaffirmed full-year 2026 guidance across all lines:
| FY2026 guidance | Range |
|---|---|
| Total net sales | $4.77–4.94B (+10–13%) |
| Jakafi | $3.22–3.27B |
| Opzelura | $750–790M |
| Heme/Onc | $800–880M |
| GAAP R&D + SG&A | $3.495–3.675B |
| Non-GAAP R&D + SG&A | $3.205–3.375B |
| COGS | ~9% of net sales |
The tell to watch: Incyte has a recent habit of raising mid-year — at Q2 2025 it lifted both Jakafi and "other oncology" guidance on the back of demand and a strong Niktimvo launch. Given the ~116% Heme/Onc growth in Q1, an upward revision to the Heme/Onc and/or Opzelura lines is a plausible positive catalyst; a mere reaffirmation could be read as underwhelming given the momentum priced into the stock.
One modeling nuance — the Vega charge lands in Q3, not Q2. The $1.25B upfront for Vega Therapeutics (closed 7/6/26) will be booked as a one-time R&D expense in Q3/FY2026 GAAP and non-GAAP results, so it should not hit the Q2 P&L — but expect updated FY expense commentary reflecting it. Don't be surprised by a large sequential opex step-up when it does land.
a) Jakafi cliff vs. the bridge. Jakafi (~$3.2B, ~2/3 of net sales) faces loss of exclusivity later this decade. The mitigation is Jakafi XR, for which management expects U.S. approval and launch mid-2026 — so a launch update / label / formulary progress on this call is important. Management frames XR as potentially capturing 10–30% of Jakafi's business by 2029. A tailwind on margins: the 2025 Novartis settlement cut the U.S. Jakafi royalty rate by 50% from Jan 1, 2025, supporting COGS at ~9%.
b) The "core ex-Jakafi" engine. This grew ~63% YoY in Q1 and management targets it approaching $3–4B by 2030, supported by four launches over ~12 months: Jakafi XR, Opzelura for moderate AD in Europe (2H26), Monjuvi in 1L DLBCL (early 2027), and povorcitinib in HS (U.S. 1Q27 / EU late 2026). Look for updated commentary on the Opzelura EU moderate-AD approval timing (2H26) and the povo HS launch prep.
c) Immunology optionality — povorcitinib. Management wants I&I to be ~1/3 of revenue by 2030. Povo now has 4 positive Phase 3 trials across HS and vitiligo; the FDA has accepted the HS NDA. Peak-sales framing: HS ~$500M–$1B; vitiligo systemic TAM ~$1.5–2B. The oral + topical (Opzelura) "continuum" in HS and vitiligo is the differentiation pitch.
Incyte comes in hot, at highs, with the market increasingly buying the diversification-away-from-Jakafi thesis. The near-term P&L bar is about beating/raising — particularly on the fast-growing Heme/Onc and Opzelura lines — while the long-term story hinges on execution of four launches over the next 12 months and de-risking the mutCALR (989), KRAS G12D (734) and povorcitinib programs. Given the reaffirmed (not raised) guidance at Q1 and the stock's run, the risk/reward skews toward needing a guidance raise and clean launch/pipeline commentary to sustain momentum; a plain in-line quarter with reaffirmed guidance could disappoint. Also flag the Vega-driven one-time R&D charge coming in Q3, which will distort GAAP/non-GAAP earnings next quarter.
Note: Figures above are drawn from Incyte's Q1 2026 and Q2 2025 releases/transcript and the July 2026 Vega closing announcement. I did not have access to sell-side consensus estimates for Q2 2026, so the "what the Street wants" framing is derived from company guidance and prior-year comps rather than a published consensus number.